Form 4: Cigna Officer's Equity Awards & Tax Withholdings

Cigna's Chief Accounting Officer, Jamie G. Kates, reported the acquisition of performance and restricted shares, along with stock options, and related tax-driven share dispositions.

Summary

• Jamie G. Kates, Chief Accounting Officer of Cigna Group (CI), reported transactions on February 27, 2026.
• Acquired 205 shares of common stock from the settlement of strategic performance shares for the 2023-2025 performance period, based on company performance goals.
• Acquired 609 restricted shares of common stock, which will vest in three equal annual installments starting March 1, 2027.
• Disposed of 71 shares of common stock at a price of $287.55 to satisfy tax obligations related to the settlement of strategic performance shares.
• Disposed of 61 shares of common stock at a price of $287.55 to satisfy tax obligations upon the vesting of restricted shares.
• Acquired 657 employee stock options with an exercise price of $287.5475, which will vest in three equal annual installments beginning March 1, 2027, and expire on February 27, 2036.
• Following these transactions, Kates beneficially owns 2,368 shares of common stock directly and 657 derivative securities (employee stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the ongoing compensation structure for a key executive and the achievement of performance goals, which aligns management's interests with the company's long-term success. The tax-related dispositions are routine and do not indicate negative sentiment.

Positives

• The Chief Accounting Officer received 205 shares of common stock as a result of the company's performance against pre-established goals for the 2023-2025 period, indicating successful achievement of targets.
• The acquisition of 609 restricted shares and 657 employee stock options aligns the executive's long-term interests with shareholder value through future vesting schedules.

Negatives

• A total of 132 shares of common stock were disposed of to cover tax obligations related to the settlement of performance shares and vesting of restricted shares, reducing direct share ownership.

Future Outlook

The future outlook includes the vesting of 609 restricted shares and 657 employee stock options in three equal annual installments, commencing March 1, 2027, and the expiration of these options on February 27, 2036.

Industry Context

StockSavvy.ai notes that these transactions are routine disclosures of executive compensation, reflecting the standard practice of granting equity awards (performance shares, restricted stock, and stock options) to align management incentives with long-term shareholder value. The disposition of shares for tax withholding is also a common and expected event following the vesting or settlement of such awards.

Stakeholder Impact

• Shareholders: The equity awards align the Chief Accounting Officer's financial interests with the company's performance, potentially fostering long-term value creation.
• Employees: These transactions reflect the company's executive compensation practices, which can influence broader compensation strategies and employee morale.

Next Steps

• The 609 restricted shares will vest in three equal annual installments beginning March 1, 2027.
• The 657 employee stock options will vest in three equal annual installments beginning March 1, 2027, and can be exercised until their expiration on February 27, 2036.

Key Dates

Keywords

Cigna, CI, Form 4, Insider Transaction, Executive Compensation, Stock Options, Restricted Stock, Performance Shares, Equity Awards